Stock HANSA BIOPHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Hansa Biopharma AB Nasdaq Stockholm

Equities

SE0002148817

Real-time Estimate Cboe Europe
Other stock markets
 09:20:02 2024-04-29 EDT 		5-day change 1st Jan Change
28.43 SEK -82.59% Intraday chart for Hansa Biopharma AB -5.78% -38.73%
04-18 Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
04-18 Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hansa Biopharma Q1 - Improved European launch support
AQ
Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
Hansa Biopharma interim report January-March 2024
AQ
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hansa Biopharma Approves SEK372 Million Directed Share Issue
MT
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)
AQ
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024
CI
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports
AQ
Hansa Biopharma Hires New CFO
MT
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
AQ
Hansa Biopharma AB Announces CFO Changes
CI
Hansa Biopharma - Improved sales prospects
AQ
Transcript : Hansa Biopharma AB, Q4 2023 Earnings Call, Feb 02, 2024
Hansa Biopharma Year-end report January-December 2023
AQ
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
AQ
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa
CI
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HNSA Stock
  4. Stock
  5. News Hansa Biopharma AB